LAUSR

Accelerated discovery and collaborative research continue to highlight the remarkable progress that has been made in the diagnosis and treatment of pediatric cancers. This manuscript highlights important discoveries on how precision oncology is being incorporated into the diagnosis and treatment of childhood cancer at the national level to identify promising new therapies using a tumor‐agnostic approach. In addition, we have highlighted three articles that incorporate genomics and cell‐free DNA to better classify, monitor and incorporate risk‐based therapies for children with medulloblastoma. Finally, we highlighted the important role of monclonal antiobody therapy in the treatment of recurrent B‐cell leukemia and newly diagnosed high‐risk neuroblastoma.